Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance

Por Chen, Kevin G., Sikic, Branimir I.
Publicado em 2012

Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet–visible high-performance liquid chromatography

Por Chin, David L., Lum, Bert L., Sikic, Branimir I.
Publicado em 2002

Identification of ovarian cancer driver genes by using module network integration of multi-omics data

Por Gevaert, Olivier, Villalobos, Victor, Sikic, Branimir I., Plevritis, Sylvia K.
Publicado em 2013

Identification of ovarian cancer driver genes by using module network integration of multi-omics data

Por Gevaert, Olivier, Villalobos, Victor, Sikic, Branimir I., Plevritis, Sylvia K.
Publicado em 2014

Clinical trial designs for testing biomarker-based personalized therapies

Por Lai, Tze Leung, Lavori, Philip W, Shih, Mei-Chiung I, Sikic, Branimir I
Publicado no Clin Trials (2012)

The miR‐200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR‐3 and MES‐OV cells

Por Brozovic, Anamaria, Duran, George E., Wang, Yan C., Francisco, E. Brian, Sikic, Branimir I.
Publicado no Mol Oncol (2015)

Expression and silencing of microtubule-associated protein Tau in breast cancer cells

Por Spicakova, Tatiana, O’Brien, Maureen M., Duran, George E., Sweet-Cordero, Alejandro, Sikic, Branimir I.
Publicado em 2010

Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis

Por Willis, Scooter, Villalobos, Victor M., Gevaert, Olivier, Abramovitz, Mark, Williams, Casey, Sikic, Branimir I., Leyland-Jones, Brian
Publicado no PLoS One (2016)

A method for detecting and correcting feature misidentification on expression microarrays

Por Brown Patrick O, Sikic Branimir I, Diehn Maximilian, Schaner Marci, Tu I-Ping, Botstein David, Fero Michael J
Publicado em 2004-09-01

A method for detecting and correcting feature misidentification on expression microarrays

Por Tu, I-Ping, Schaner, Marci, Diehn, Maximilian, Sikic, Branimir I, Brown, Patrick O, Botstein, David, Fero, Michael J
Publicado em 2004

A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin (IFOX) in Previously Untreated Patients with Metastatic Colorectal Cancer

Por Fisher, George A., Kuo, Timothy, Ramsey, Meghan, Schwartz, Erich, Rouse, Robert V., Cho, Cheryl D., Halsey, Joanne, Sikic, Branimir I.
Publicado em 2008

Chromatin-remodeling complex SWI/SNF controls multidrug resistance by transcriptionally regulating the drug efflux pump ABCB1

Por Dubey, Ramin, Lebensohn, Andres, Bahrami-Nejad, Zahra, Marceau, Caleb, Champion, Magali, Gevaert, Olivier, Sikic, Branimir I., Carette, Jan E., Rohatgi, Rajat
Publicado no Cancer Res (2016)

Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures

Por Juric, Dejan, Sale, Sanja, Hromas, Robert A., Yu, Ron, Wang, Yan, Duran, George E., Tibshirani, Robert, Einhorn, Lawrence H., Sikic, Branimir I.
Publicado em 2005

Amplification of Whole Tumor Genomes and Gene-by-Gene Mapping of Genomic Aberrations from Limited Sources of Fresh-Frozen and Paraffin-Embedded DNA

Por Bredel, Markus, Bredel, Claudia, Juric, Dejan, Kim, Young, Vogel, Hannes, Harsh, Griffith R., Recht, Lawrence D., Pollack, Jonathan R., Sikic, Branimir I.
Publicado em 2005

Mechanisms of Resistance to Cabazitaxel

Por Duran, George E., Wang, Yan C., Francisco, E. Brian, Rose, John C., Martinez, Francisco J., Coller, John, Brassard, Diana, Vrignaud, Patricia, Sikic, Branimir I.
Publicado no Mol Cancer Ther (2014)

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers

Por Moisan, Francois, Francisco, Edgar B., Brozovic, Anamaria, Duran, George E., Wang, Yan C., Chaturvedi, Shalini, Seetharam, Shobha, Snyder, Linda A., Doshi, Parul, Sikic, Branimir I.
Publicado no Mol Oncol (2014)

A Network Model of a Cooperative Genetic Landscape in Brain Tumors

Por Bredel, Markus, Scholtens, Denise M., Harsh, Griffith R., Bredel, Claudia, Chandler, James P., Renfrow, Jaclyn J., Yadav, Ajay K., Vogel, Hannes, Scheck, Adrienne C., Tibshirani, Robert, Sikic, Branimir I.
Publicado no JAMA (2009)

Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors

Por Kunz, Pamela L., He, Aiwu R., Colevas, A. Dimitrios, Pishvaian, Michael J., Hwang, Jimmy J., Clemens, Pamela L., Messina, Marianne, Kaleta, Remigiusz, Abrahao, Fernanda, Sikic, Branimir I., Marshall, John L.
Publicado em 2012

Phase I Study of Valspodar (PSC-833) with Mitoxantrone and Etoposide in Refractory and Relapsed Pediatric Acute Leukemia: A Report from the Children’s Oncology Group

Por O’Brien, Maureen M., Lacayo, Norman J., Lum, Bert L., Kshirsagar, Smita, Buck, Steven, Ravindranath, Yaddanapudi, Bernstein, Mark, Weinstein, Howard, Chang, Myron N., Arceci, Robert J., Sikic, Branimir I., Dahl, Gary V.
Publicado em 2010

Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement

Por Vrdoljak, Eduard, Bodoky, Gyorgy, Jassem, Jacek, Popescu, Razvan A., Mardiak, Jozef, Pirker, Robert, Čufer, Tanja, Bešlija, Semir, Eniu, Alexandru, Todorović, Vladimir, Kubáčková, Kateřina, Kurteva, Galia, Tomašević, Zorica, Sallaku, Agim, Smichkoska, Snezhana, Bajić, Žarko, Šikić, Branimir I.
Publicado no Oncologist (2016)